Growth momentum Fortrea is in a growth phase with a strategic emphasis on expanding capabilities through recent facility acquisitions in Texas and a renewed focus on returning to growth under new CFO Jason Knoblauch, signaling openness to expanded client engagements and larger scale programs.

end-to-end platform The company highlights an end-to-end clinical development platform spanning phase I–IV, clinical pharmacology, technology-enabled trial solutions, and post-approval services, presenting opportunities to cross-sell integrated services to biopharma and medical device clients seeking seamless trial execution.

customer continuity Recent agreements with Worldwide Clinical Trials to support continuity for clients, employees, and ongoing programs suggest Fortrea prioritizes long-term relationships and seamless program transitions, a selling point for customers worried about program stability during organizational changes.

capital appetite Significant capital investments in Texas facilities indicate Fortrea has both the financial wherewithal and strategic demand to scale operations, implying potential for larger, multi-site trials and enhanced bioanalytical and biospecimen storage capabilities to support complex programs.

market visibility Publicized quarterly revenue outcomes and active investor engagement at major healthcare conferences reflect a clearer growth narrative and market transparency, creating opportunities to approach Fortrea with growth-oriented proposals and data-driven ROI analyses for prospective clients.